BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Recruiting | N/A | 200 | Europe, Canada, US, RoW | | Immune Oncology Research Institute | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 07/32 | 07/32 | | |
